SEATTLE, April 30 -- The epilepsy drug levetiracetam (Keppra) does not appear to be effective for prevention of chronic daily headache, researchers said here.
Action Points Explain that the epilepsy drug levetiracetam did not significantly increase the headache-free rate for patients with chronic daily headache compared with placebo.Note, however, that there was a significant reduction in disability and reduced pain severity in the treatment group, and the findings show that there is a subpopulation of chronic daily headache patients for whom levetiracetam remains a therapeutic option.Note that this study was published as an abstract and presented orally at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
Levetiracetam drug achieved a 3.9% increase in headache-free performance over placebo, but the trend did not reach statistical significance, Roy Beran, M.D., of the University of New South Wales, and colleagues reported at the American Academy of Neurology meeting.
SEATTLE, April 30 -- The epilepsy drug levetiracetam (Keppra) does not appear to be effective for prevention of chronic daily headache, researchers said here. Levetiracetam drug achieved a 3.9% increase in headache-free performance over placebo, but the trend did not reach statistical significance, Roy Beran, M.D., of the University of New South Wales, and colleagues reported at the American Academy of Neurology meeting.
